Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Berkowitz

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Invasive Cardiology|January 13, 2001
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary interventionK R Campbell, K W Mahaffey, B E Lewis, et al.
American Heart Journal|February 15, 2001
Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary interventionM Madan, S D Berkowitz, D J Christie, et al.
Blood|July 1, 1987
Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individualsJ Batlle, M F Lopez-Fernandez, A Lopez-Borrasca, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Circulation|May 20, 1998
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]D B Mark, P A Cowper, S D Berkowitz, et al.
American Heart Journal|June 30, 2000
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockadeD J Kereiakes, S D Berkowitz, A M Lincoff, et al.
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
Journal of Thrombosis and Haemostasis : JTH|May 10, 2014
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteersM Levi, K T Moore, C F Castillejos, et al.
Journal of Thrombosis and Haemostasis : JTH|October 3, 2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind studyC W Colwell, S D Berkowitz, B L Davidson, et al.
The American Journal of Cardiology|March 23, 2000
Efficacy of abciximab readministration in coronary interventionM Madan, D J Kereiakes, J B Hermiller, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Invasive Cardiology|January 13, 2001
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary interventionK R Campbell, K W Mahaffey, B E Lewis, et al.
American Heart Journal|February 15, 2001
Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary interventionM Madan, S D Berkowitz, D J Christie, et al.
Blood|July 1, 1987
Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individualsJ Batlle, M F Lopez-Fernandez, A Lopez-Borrasca, et al.
Journal of the American College of Cardiology|August 26, 1998
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study GroupS D Berkowitz, D C Sane, K N Sigmon, et al.
Circulation|May 20, 1998
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]D B Mark, P A Cowper, S D Berkowitz, et al.
American Heart Journal|June 30, 2000
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockadeD J Kereiakes, S D Berkowitz, A M Lincoff, et al.
Circulation|June 3, 1997
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I InvestigatorsS D Berkowitz, C B Granger, K S Pieper, et al.
Journal of Thrombosis and Haemostasis : JTH|May 10, 2014
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteersM Levi, K T Moore, C F Castillejos, et al.
Journal of Thrombosis and Haemostasis : JTH|October 3, 2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind studyC W Colwell, S D Berkowitz, B L Davidson, et al.
The American Journal of Cardiology|March 23, 2000
Efficacy of abciximab readministration in coronary interventionM Madan, D J Kereiakes, J B Hermiller, et al.
Pageof 5